Limits...
Assessment of Growth Disturbance in Japanese Children with IBD.

Shono T, Kato M, Aoyagi Y, Haruna H, Fujii T, Kudo T, Ohtsuka Y, Shimizu T - Int J Pediatr (2010)

Bottom Line: We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and cytokines, and the amount of corticosteroid administered in children with Crohn's disease (CD, n = 15) and ulcerative colitis (UC, n = 18).Our results suggest that growth retardation is already present before the initial visit in children with CD, and chronic inflammation may be responsible this growth disturbance.Moreover, the amount of PSL used may contribute to growth retardation by decreasing the serum levels of IGF-I in children with IBD.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

ABSTRACT
In Japan, there is as yet no report on growth retardation in children with IBD. We therefore investigated the cause of growth retardation in Japanese children with IBD. We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and cytokines, and the amount of corticosteroid administered in children with Crohn's disease (CD, n = 15) and ulcerative colitis (UC, n = 18). Our results suggest that growth retardation is already present before the initial visit in children with CD, and chronic inflammation may be responsible this growth disturbance. Moreover, the amount of PSL used may contribute to growth retardation by decreasing the serum levels of IGF-I in children with IBD.

No MeSH data available.


Related in: MedlinePlus

Changes in % standard weight in children with CD and those with UC.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2864444&req=5

fig3: Changes in % standard weight in children with CD and those with UC.

Mentions: Compared with the 1-year period before the start of treatment, % standard weight in the children with CD at diagnosis was significantly lower (P < .01) but showed a significant increase 1 year subsequent to the start of treatment (P < .01). On the other hand, there was no significant difference between the pretreatment and posttreatment levels. In subjects with UC, compared with the 1-year period before starting treatment, % standard weight at diagnosis was found to be significantly lower (P < .05), and although posttreatment levels tended to be elevated, we found no significant difference between the pretreatment and posttreatment levels (Figure 3).


Assessment of Growth Disturbance in Japanese Children with IBD.

Shono T, Kato M, Aoyagi Y, Haruna H, Fujii T, Kudo T, Ohtsuka Y, Shimizu T - Int J Pediatr (2010)

Changes in % standard weight in children with CD and those with UC.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2864444&req=5

fig3: Changes in % standard weight in children with CD and those with UC.
Mentions: Compared with the 1-year period before the start of treatment, % standard weight in the children with CD at diagnosis was significantly lower (P < .01) but showed a significant increase 1 year subsequent to the start of treatment (P < .01). On the other hand, there was no significant difference between the pretreatment and posttreatment levels. In subjects with UC, compared with the 1-year period before starting treatment, % standard weight at diagnosis was found to be significantly lower (P < .05), and although posttreatment levels tended to be elevated, we found no significant difference between the pretreatment and posttreatment levels (Figure 3).

Bottom Line: We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and cytokines, and the amount of corticosteroid administered in children with Crohn's disease (CD, n = 15) and ulcerative colitis (UC, n = 18).Our results suggest that growth retardation is already present before the initial visit in children with CD, and chronic inflammation may be responsible this growth disturbance.Moreover, the amount of PSL used may contribute to growth retardation by decreasing the serum levels of IGF-I in children with IBD.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

ABSTRACT
In Japan, there is as yet no report on growth retardation in children with IBD. We therefore investigated the cause of growth retardation in Japanese children with IBD. We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and cytokines, and the amount of corticosteroid administered in children with Crohn's disease (CD, n = 15) and ulcerative colitis (UC, n = 18). Our results suggest that growth retardation is already present before the initial visit in children with CD, and chronic inflammation may be responsible this growth disturbance. Moreover, the amount of PSL used may contribute to growth retardation by decreasing the serum levels of IGF-I in children with IBD.

No MeSH data available.


Related in: MedlinePlus